Pat Gulhati, MD, PhD, discusses findings from a comprehensive analysis of genetic, immunological, and signaling pathway variations in pancreatic cancer.

Lung cancer is by far the most lethal form of cancer in the U.S., accounting for about 1 in 5 of all cancer deaths.

Johns Hopkins Medicine scientists say they have found a pattern of so-called epigenetic "marks" in a transition state between ...

AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announces plans to launch its microRNA Signature ...

A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...

Lung cancer screening with low-dose CT could have saved tens of thousands of lives — if only we'd listened to the data back ...

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in ...

Cigarette smoking declines over the past several decades prevented an estimated 3.8 million lung cancer deaths, according to ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...

New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...